---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000922"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:38:27.331881+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DOJ closes inquiry into Cassava Sciences; ends all government investigations

## Summary
- DOJ Fraud Section closed previously-disclosed inquiry into research misconduct allegations.
- The related indictment in United States v. Wang was dismissed with prejudice on Oct 23, 2025.
- Company previously settled SEC negligence charges in Sept 2024 with monetary penalty.
- CEO Richard Barry says company remains focused on developing treatment for TSC-related epilepsy.
- No further government investigations pending against Cassava Sciences.

## SEC filing metadata
- accession: 0001171843-26-000922
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184326000922/0001171843-26-000922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184326000922/f8k_021926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000922
- JSON: https://secwatch.observer/filing/0001171843-26-000922.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.